Galapagos increases share capital through subscription right exercises
September 27 2022 - 4:01PM
Mechelen, Belgium;
27 September
2022,
22.01
CET; regulated
information – Galapagos NV (Euronext & NASDAQ:
GLPG) announces a share capital increase arising from
subscription right exercises.
Galapagos issued 107,000 new ordinary shares on
27 September 2022, for a total capital increase (including issuance
premium) of EUR 3,076,250.
Pursuant to the subscription right exercise
program for Galapagos’ executive committee, the members of the
executive committee automatically are committed to exercise a
minimum number of subscription rights, subject to certain
conditions. In accordance with the rules of this program, one
executive committee member exercised 5,000 subscription rights.
In accordance with Belgian transparency
legislation1, Galapagos also wishes to note that its total share
capital currently amounts to EUR 356,111,899.01, the total number
of securities conferring voting rights amounts to 65,835,511, which
is also the total number of voting rights (the denominator), and
all securities conferring voting rights and all voting rights are
of the same category. The total number of rights (formerly known as
‘warrants’) to subscribe to not yet issued securities conferring
voting rights is (i) 10,763,717 subscription rights under several
outstanding personnel subscription right plans, which equals
10,763,717 voting rights that may result from the exercise of those
subscription rights, and (ii) 1 subscription right issued to Gilead
Therapeutics to subscribe for a maximum number of shares that is
sufficient to bring the shareholding of Gilead (and its affiliated
companies) to 29.9% of the actually issued and outstanding shares
after the exercise of such subscription right. Galapagos does not
have any convertible bonds or shares without voting rights
outstanding.
About GalapagosGalapagos is a
fully integrated biotechnology company focused on discovering,
developing, and commercializing innovative medicines. We are
committed to improving patients’ lives worldwide by targeting
diseases with high unmet needs. Our R&D capabilities cover
multiple drug modalities, including small molecules and cell
therapies. Our portfolio comprises discovery through to Phase 4
programs in inflammation, oncology, fibrosis, and other
indications. Our first medicine for rheumatoid arthritis and
ulcerative colitis is approved and available in the European Union,
Norway, United Kingdom, and Japan. For additional information,
please visit www.glpg.com or follow us
on LinkedIn or Twitter.
ContactInvestors:Sofie Van
GijselHead of Investor Relations+1 781 296 1143
Sandra CauwenberghsDirector Investor Relations+32 495 58 46
63ir@glpg.com
Media:Marieke VermeerschHead of Corporate
Communication+32 479 490 603media@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
1 Belgian Act of
2 May 2007 on the disclosure of major shareholdings in issuers
whose shares are admitted to trading on a regulated market (as
amended from time to time).
- Galapagos increases share capital through subscription right
exercises
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024